NasdaqGM - Nasdaq Real Time Price USD

MediWound Ltd. (MDWD)

17.95

+0.30

+(1.70%)

At close: April 22 at 4:00:01 PM EDT

18.30

+0.35

+(1.95%)

Pre-Market: 8:36:47 AM EDT

Those who invested in MediWound (NASDAQ:MDWD) five years ago are up 30%

It hasn't been the best quarter for MediWound Ltd. ( NASDAQ:MDWD ) shareholders, since the share price has fallen 15...

Simply Wall St. 7 days ago

MDWD
+1.70%
Loss-Making MediWound Ltd. (NASDAQ:MDWD) Expected To Breakeven In The Medium-Term

MediWound Ltd. ( NASDAQ:MDWD ) is possibly approaching a major achievement in its business, so we would like to shine...

Simply Wall St. last month

MDWD
+1.70%
MediWound Ltd (MDWD) Q4 2024 Earnings Call Highlights: Revenue Growth Amid Rising Losses

MediWound Ltd (MDWD) reports increased revenue and strategic advancements, despite a widening net loss and higher expenses in Q4 2024.

GuruFocus.com last month

MDWD
+1.70%
MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates

MediWound (MDWD) delivered earnings and revenue surprises of 38.98% and 1.53%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

MDWD
+1.70%
MediWound: Q4 Earnings Snapshot

YAVNE, Israel (AP) — MediWound Ltd. (MDWD) on Wednesday reported a loss of $3.9 million in its fourth quarter. The Yavne, Israel-based company said it had a loss of 36 cents per share. The results exceeded Wall Street expectations.

Associated Press Finance last month

MDWD
+1.70%
MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcers Expanded strategic research collaborations with industry leaders, now including Kerecis $20 million in revenue for 2024; $24 million projected for 2025; $44 million in cash as of Year-End 2024 Conference call today, March 19 at 8:30am Eastern Time YAVNE, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today ann

GlobeNewswire last month

MDWD
+1.70%
MediWound to Report Fourth Quarter and Full Year 2024 Financial Results

Conference call and webcast scheduled for Wednesday, March 19th at 8:30 a.m. Eastern TimeYAVNE, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2024 on Wednesday, March 19, 2025. Following the release, MediWound’s management will host a conference call and live webcast at 8:30 a.m.

GlobeNewswire last month

MDWD
+1.70%
Madrigal (MDGL) Reports Q4 Loss, Tops Revenue Estimates

Madrigal (MDGL) delivered earnings and revenue surprises of 34.22% and 1.69%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

MDWD
+1.70%
MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care

Findings in Burns Journal confirm NexoBrid’s superiority over standard of care in pediatric patients with deep thermal burnsNexoBrid is approved for pediatric use in the U.S., E.U. and Japan YAVNE, Israel, Feb. 25, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the publication of its Phase III Children Innovative Debridement Study (CIDS) in Burns, the peer-reviewed Journal of the International S

GlobeNewswire last month

MDWD
+1.70%
MediWound to Present at the 45th Annual TD Cowen Health Care Conference

YAVNE, Israel, Feb. 24, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Officer Ofer Gonen will present a corporate overview at the upcoming 45th Annual TD Cowen Health Care Conference, taking place in Boston, MA on Wednesday, March 5, 2025, at 11:50 AM ET. To listen to the live webcast of the presentation, please register here. A replay of the event will also be posted to Me

GlobeNewswire last month

MDWD
+1.70%
MediWound commences Phase III trial for venous leg ulcers treatment

The double-blind trial is set to take place across 40 European and US sites.

Clinical Trials Arena 2 months ago

MDWD
+1.70%
MediWound Launches Phase III Trial Evaluating EscharEx for Treating Venous Leg Ulcers

MediWound (MDWD) said Wednesday it has initiated a global phase III trial evaluating EscharEx for th

PREMIUM
MT Newswires 2 months ago

MDWD
+1.70%
MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of patients complete treatment, expected in mid-2026 Strategic research collaborations with Solventum, Mölnlycke, and MIMEDX YAVNE, Israel, Feb. 12, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the initiation of VALUE, a global, pivotal Phas

GlobeNewswire 2 months ago

MDWD
+1.70%
MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

YAVNE, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Officer Ofer Gonen will take part in a fireside chat during the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual). The fireside chat, hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer, will take place on Wednesday, February 1

GlobeNewswire 2 months ago

MDWD
+1.70%
MediWound Ltd.'s (NASDAQ:MDWD) high institutional ownership speaks for itself as stock continues to impress, up 15% over last week

Key Insights Given the large stake in the stock by institutions, MediWound's stock price might be vulnerable to their...

Simply Wall St. 2 months ago

MDWD
+1.70%
MediWound (MDWD) Surges 8.5%: Is This an Indication of Further Gains?

MediWound (MDWD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks 2 months ago

MDWD
+1.70%
NKTR
Mediwound Advances in Enzymatic Therapeutics with Strategic Expansions

Mediwound ( (MDWD) ) has shared an announcement. Mediwound has announced significant progress in its product pipeline, highlighting the commercial potential and market expansion of its key products, NexoBrid and EscharEx. With a strong balance sheet, strategic collaborations, and substantial support from government contracts, the company aims to scale up operations to meet global demand by the end of 2025. The company has a diversified portfolio and is poised to challenge existing market players

TipRanks 3 months ago

MDWD
+1.70%
We're Keeping An Eye On MediWound's (NASDAQ:MDWD) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 3 months ago

MDWD
+1.70%
MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx® Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025

YAVNE, Israel, Dec. 17, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced it will host a virtual Key Opinion Leader (KOL) event on Wednesday, January 8, 2025, at 10:00 AM ET. The event will focus on EscharEx®, an innovative biologic drug in late-stage clinical development for chronic wound debridement, including the upcoming Phase III VALUE study in venous leg ulcers (VLUs) and EscharEx’s commercia

GlobeNewswire 4 months ago

MDWD
+1.70%
MediWound Executives Acquire 18,462 Shares, Signaling Confidence in Company’s Future

Mediwound ( (MDWD) ) just unveiled an announcement. In a recent announcement, MediWound Ltd. reported that key members of its Board of Directors and the CEO have purchased a total of 18,462 ordinary shares in the open market. These acquisitions, conducted between December 9 and December 13, 2024, reflect the leadership’s confidence in the company’s future prospects and adherence to insider trading policies. This move is likely to bolster stakeholder confidence and might enhance the company’s sta

TipRanks 4 months ago

MDWD
+1.70%

Performance Overview

Return	MDWD	S&P 500 (^GSPC)
YTD	+0.84%	-10.10%
1-Year	+13.90%	+5.53%
3-Year	+16.03%	+23.78%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

MediWound Ltd. (MDWD)

Those who invested in MediWound (NASDAQ:MDWD) five years ago are up 30%

Loss-Making MediWound Ltd. (NASDAQ:MDWD) Expected To Breakeven In The Medium-Term

MediWound Ltd (MDWD) Q4 2024 Earnings Call Highlights: Revenue Growth Amid Rising Losses

MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates

MediWound: Q4 Earnings Snapshot

MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

MediWound to Report Fourth Quarter and Full Year 2024 Financial Results

Madrigal (MDGL) Reports Q4 Loss, Tops Revenue Estimates

MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care

MediWound to Present at the 45th Annual TD Cowen Health Care Conference

MediWound commences Phase III trial for venous leg ulcers treatment

MediWound Launches Phase III Trial Evaluating EscharEx for Treating Venous Leg Ulcers

MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers

MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

MediWound Ltd.'s (NASDAQ:MDWD) high institutional ownership speaks for itself as stock continues to impress, up 15% over last week

MediWound (MDWD) Surges 8.5%: Is This an Indication of Further Gains?

Mediwound Advances in Enzymatic Therapeutics with Strategic Expansions

We're Keeping An Eye On MediWound's (NASDAQ:MDWD) Cash Burn Rate

MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx® Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025

MediWound Executives Acquire 18,462 Shares, Signaling Confidence in Company’s Future

Performance Overview